ライブ
FierceBiotechFDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on boardFierceBiotechFDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting10x Genomics NewsVanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG) - Stock TitanEndpoints NewsFDA debuts plan to collect real-time clinical trial dataEndpoints NewsThe crown for healthcare admin tech is still up for grabsEndpoints NewsPfizer delays patent cliff for blockbuster VyndamaxEndpoints NewsHikma and Amarin's generic drug case heads to Supreme Court argumentsBioPharma DivePfizer deals extend patent life for a top-selling rare disease drugFierceBiotechErasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient deathFierceBiotechIncyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off RinvoqFierceBiotechAbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisitionFierceBiotechProtagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits
IMI 2025年9月24日

IMI Update Highlights Continued Engagement with Myopia Management - Review of Optometry

IMI Update Highlights Continued Engagement with Myopia Management - Review of Optometry

原文
本文は利用できません。元の情報源をご確認ください。